Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
DYSLIPIDEMIA / STATE OF THE ART PAPER
Incorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines
1
Faculty of Medicine, Lazarski University, Warsaw, Poland
2
Clinical Department of Internal Medicine, Endocrinology, Diabetology and Nephrology, Czerniakowski Hospital, Warsaw, Poland
3
1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
4
Doctoral School, Medical University of Warsaw, Poland
5
Clinical Department of Internal Medicine, Endocrinology, Diabetology and Nephrology, Czerniakowski Hospital, Poland
6
Faculty of Medicine, the John Paul II Catholic University of Lublin, Poland
7
Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Poland
8
Ciccarone Center for the Prevention of Cardiovascular Disease, School of Medicine, Johns Hopkins University, United States
Submission date: 2025-10-09
Acceptance date: 2025-10-15
Online publication date: 2025-10-20
Corresponding author
Jakub Michal Zimodro
1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland
1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland
KEYWORDS
TOPICS
ABSTRACT
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
